- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis
-
- Shaily Arora
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Sanjeeve Balasubramaniam
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Wei Zhang
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Lijun Zhang
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Rajeshwari Sridhara
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Dianne Spillman
- 2Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Jaigi P. Mathai
- 3Health Canada, Ottawa, Ontario, Canada.
-
- Bradley Scott
- 3Health Canada, Ottawa, Ontario, Canada.
-
- Sarah J. Golding
- 4Therapeutic Goods Administration, Symonston, Australia.
-
- Michael Coory
- 4Therapeutic Goods Administration, Symonston, Australia.
-
- Richard Pazdur
- 2Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.
-
- Julia A. Beaver
- 1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Search this article
Description
<jats:title>Abstract</jats:title><jats:p>On September 17, 2019, FDA granted accelerated approval to pembrolizumab plus lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation. The submission and review of this application was conducted through an FDA Oncology Center of Excellence initiative named Project Orbis whereby the FDA, the Australian Therapeutic Goods Administration, and Health Canada were able to simultaneously review and collaborate, rendering simultaneous approval decisions in all countries. Accelerated approval of the pembrolizumab plus lenvatinib combination was based on a single-arm trial of 94 patients, with previously treated metastatic endometrial cancer whose tumors were not MSI-H/dMMR. Efficacy was demonstrated on the basis of an objective response rate of 38.3% (95% confidence interval, 28.5%–48.9%) with 10 complete responses (10.6%) accompanied by supportive durations of response. Trials to confirm clinical benefit of this combination are ongoing. Here, we summarize the benefit–risk analysis supporting accelerated approval of the pembrolizumab plus lenvatinib combination and describe the methodology for the first Project Orbis review.</jats:p>
Journal
-
- Clinical Cancer Research
-
Clinical Cancer Research 26 (19), 5062-5067, 2020-10-01
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1360861710809232768
-
- ISSN
- 15573265
- 10780432
-
- Data Source
-
- Crossref